Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-line treatment for patients with Undifferentiated Pleomorphic Sarcoma
The combination of epirubicin, ifosfamide, and nivolumab is a safe, feasible, and highly active treatment for advanced UPS.
Authors
- Ana Sebio (ORCID: https://orcid.org/0000-0003-3333-2370)
- Claudia Valverde (ORCID: https://orcid.org/0000-0003-4107-8616)
- José L. Mondaza-Hernández (ORCID: https://orcid.org/0000-0002-5642-3796)
- Javier Fernández-Jara (ORCID: https://orcid.org/0000-0003-3546-6356)
- Carlos López-Jiménez (ORCID: https://orcid.org/0000-0001-5864-5117)
- Patricio Ledesma
- C. Romagosa
- Roberto Díaz (ORCID: https://orcid.org/0000-0003-1371-3264)
- Laura Hernández-Vargas (ORCID: https://orcid.org/0000-0002-2699-8580)
- Irene Carrasco
- Nadia Hindi
- David S. Moura
- Javier Martinez-Trufero
- Jose Merino
- Enrique Gonzalez-Billalabeitia
- Maria Augusta Carrera
- Josefina Cruz-Jurado
- J. Martin-Broto
- Antonio Gutierrez
- Rafael Ramos
- Maria Dolores Garmendia
Institutions
- Hebron University (PS)
- Hospital Universitario de Canarias (ES)
- Hospital de Sant Pau (ES)
- Hospital Universitari i Politècnic La Fe (ES)
- Hospital Universitario 12 De Octubre (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Hospital Universitario Miguel Servet (ES)
- Swedish Society of Oncology (SE)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Hospital Universitario Son Espases (ES)
- Hospital Universitario Virgen del Rocío (ES)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1158/1078-0432.ccr-26-0032
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00